


BREAKING THROUGH THE FIREWALL: NEW THERAPEUTIC STRATEGIES TO DISRUPT CANCER'S OPERATING SYSTEMS



**Saturday, 10 September,
18:30 - 20:00 CEST**

**7.3.Q - Quimper Auditorium, Hall 7, Level 7.3
Paris Expo Porte de Versailles, Paris, France
Chair: Martin Reck, MD, PhD**

Then available on demand until Tuesday, 20 September 2022

Join us to hear an international faculty of experts present an array of novel approaches to tackling new targets in cancer, including MDM2-p53 antagonists in soft tissue sarcomas and other tumor types, HER2 and KRAS inhibitors in NSCLC and other cancers, and T-cell engagers in solid tumors.

18:30 - 18:35 WELCOME AND INTRODUCTIONS

Martin Reck, MD, PhD

18:35 - 19:05 DEVELOPMENT OF AN MDM2-P53
ANTAGONIST FOR STS AND OTHER
INDICATIONS

Patrick Schöffski, MD, MPH

19:05 - 19:25 TARGETING HER2 AND KRAS TO DELIVER
BREAKTHROUGH THERAPIES

Egbert Smit, MD, PhD

19:25 - 19:45 T-CELL ENGAGERS: CHANGE OF THE
TREATMENT PARADIGM IN SOLID TUMORS


Martin Reck, MD, PhD

19:45 - 19:55 EXPERT PANEL Q&A

Moderator: Martin Reck, MD, PhD

19:55 - 20:00 CLOSING REMARKS

Martin Reck, MD, PhD



LET'S COLLABORATE
ONCOLOGY FROM BOEHRINGER INGELHEIM

